• 1
    Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results of a Workshop. Osteoarthritis Cartilage 1996; 4: 21743.
  • 2
    Dougados M, Devogelaer JP, Annefeld M, Avouac B, Bouvenot G, Cooper C, et al. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996; 55: 5527.
  • 3
    Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994; 21 Suppl 41: 6571.
  • 4
    Bouvenot G. Considerations on the methodology of studies evaluating treatments for osteoarthritis. Rev Rhum Engl Ed 1994; 61: 746.
  • 5
    Dougados M. Clinical assessment of osteoarthritis in clinical trials. Curr Opin Rheumatol 1995; 7: 8791.
  • 6
    Bellamy N, Kirwan J, Altman R, Boers M, Brandt K, Brooks P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis: consensus development at OMERACT III. J Rheumatol 1997; 24: 799802.
  • 7
    Mauviel A, Daireaux M, Hartmann DJ, Galera P, Loyau G, Pujol JP. Effets des insaponifiables d'avocat et de soja (PIAS) sur la production de collagène par des cultures de synoviocytes, chondrocytes articulaires et fibroblastes dermiques. Rev Rhum Mal Ostéoartic 1989; 56: 20711.
  • 8
    Mauviel A, Loyau G, Pujol JP. Effet des insaponifiables d'avocat/soja (Piasclédine®) sur l'activité collagénolytique de cultures de synoviocytes rhumatoïdes humains et de chondrocytes articulaires de lapin traités par l'interleukine 1. Rev Rhum Mal Ostéoartic 1991; 58: 2415.
  • 9
    Henrotin Y, Labasse A, Zheng SX, De Groote D, Jaspar JM, Guillou GB, et al. Effects of three avocado/soybean unsaponifiable mixtures on human articular chondrocytes metabolism. Clin Rheumatol 1998; 17: 319.
  • 10
    Boumediene K, Felisaz N, Bogdanowicz P, Galera P, Guillou GB, Pujol J-P. Avocado/soya unsaponifiables enhance expression of transforming growth factor β1 and β2 in cultured articular chondrocytes. Arthritis Rheum 1999; 42: 14856.
  • 11
    Mazières B, Tempesta C, Tiechard M, Vaguier G. Pathologic and biochemical effects of a lipidic avocado and soya extract on an experimental post-contusive model of OA [abstract]. Osteoarthritis Cartilage 1993; 1: 46.
  • 12
    Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A. Mid-term efficacy and safety of avocado and soya unsaponifiables (ASU) in the treatment of knee and hip osteoarthritis: results of a three-month prospective, randomized, double-blind, placebo-controlled, parallel groups, multicenter clinical trial. Rev Rhum Engl Ed 1997; 64: 82534.
  • 13
    Maheu E, Mazières B, Valat JP, Loyau G, Le Loët X, Bourgeois P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998; 41: 8191.
  • 14
    Lequesne M, Méry C, Samson M, Gérard P. Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol 1987; 65 Suppl: 859.
  • 15
    Dougados M, Nguyen M, Berdah L, Lequesne M, Mazières B, Vignon E. Evaluation of the structural (radiological) effect of diacerein in osteoarthritis of the hip: a 3-year placebo-controlled study [abstract]. Osteoarthritis Cartilage 1999; 7 Suppl A: S31.
  • 16
    Reginster JY, Deroisy R, Rovati L, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 2516.
  • 17
    Listrat V, Ayral X, Patarnello F, Bonvarlet JP, Simonnet J, Amor B, et al. Arthroscopic evaluation of potential structure-modifying activity of hyaluronan (Hyalgan®) in osteoarthritis of the knee. Osteoarthritis Cartilage 1997; 5: 15360.
  • 18
    Lequesne M, Méry C. European guidelines for clinical trials of new rheumatic drugs. EULAR Bull 1980; 9 Suppl: 1715.
  • 19
    Kellgren JH, Lawrence DM. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957; 16: 494502.
  • 20
    Reis P, Nahal-Saïd R, Ravaud Ph, Dougados M, Amor B. Are radiological joint space width of normal hips asymmetrical? Ann Rheum Dis 1999; 58: 2469.
  • 21
    Armbuster TG, Guerra J, Jr, Resnick D, Goergen TG, Feingold ML, Niiwayama G, et al. The adult hip: an anatomic study. Radiology 1978; 128: 110.
  • 22
    Lequesne M, Cadet C, Winkler P, Rodriguez P, Wilhelm F. How rapid is the narrowing of the joint space in primary osteoarthritis of the hip (OAH) within 3 years?. Validity of its measure for a long term trial [abstract]. 17th ILAR Congress Rheumatol; 1989; Rio de Janeiro. p.52.
  • 23
    Huskisson EC. Measurement of pain. Lancet 1974; 2: 112731.
  • 24
    Europ Agency Eval Med Products. International Conference Harmonisation (ICH) Topic E9-Step 4 Consensus Guideline: note for guidance on statistical principles for clinical trials. London: European Agency; 1998 Feb. 5. p. 245.
  • 25
    Dougados M, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazières B, et al. Radiological progression of hip osteoarthritis: definition, risk factors and correlations with clinical status. Ann Rheum Dis 1996; 55: 35662.
  • 26
    Goker B, Aida M, Doughan AM, Schnitzer TJ, Block JA. Quantification of progressive joint space narrowing in osteoarthritis of the hip: longitudinal analysis of the contralateral hip after total hip arthroplasty. Arthritis Rheum 2000; 43: 9894.
  • 27
    Lequesne M. Quantitative measurement of joint space during progression of osteoarthritis: “Condrometry.” In: KuettnerK, GoldbergV, editors. Osteoarthritis disorders. Rosemont (IL) American Academy of Orthopaedic Surgeons; 1995. p. 42744.
  • 28
    Ravaud Ph, Dougados M. Radiographic assessment in osteoarthritis. J Rheumatol 1997; 24: 78691.
  • 29
    Conrozier T, Lequesne MG, Tron AM, Mathieu P, Berdah L, Vignon E. The effects of position on the radiographic joint space in osteoarthritis of the hip. Osteoarthritis Cartilage 1997; 5: 1722.
  • 30
    Altman RD, Fries JF, Bloch DA, Carstens J, Cooke DT, Genant H, et al. Radiographic assessment of progression in osteoarthritis. Arthritis Rheum 1987; 30: 121425.
  • 31
    Ravaud Ph, Auleley GR, Chastang C, Rousselin B, Paolozzi L, Amor B, et al. Knee joint space width measurement: an experimental study of the influence of radiographic procedure and joint positioning. Br J Rheumatol 1996; 35: 7616.
  • 32
    Ravaud Ph, Giraudeau B, Auleley GR, Chastang C, Poiraudeau S, Ayral X, et al. Radiographic assessment of knee osteoarthritis: reproducibility and sensitivity to change. J Rheumatol 1996; 23: 175664.
  • 33
    Buckland-Wright C. Radiographic assessment of osteoarthritis: comparison between existing methodologies. Osteoarthritis Cartilage 1999; 7: 4303.
  • 34
    Auleley GR, Giraudeau B, Dougados M, Ravaud PH. Radiographic assessment of hip osteoarthritis progression: impact of reading procedures for longitudinal studies. Ann Rheum Dis 2000; 59: 4227.
  • 35
    Lequesne M, Cadet C, Auleley GR. New techniques and reproducibility of the manual measurement of the osteoarthritic hip joint space [abstract]. Osteoarthritis Cartilage 2000; 8: 156.
  • 36
    Dieppe P, Cushnagan J, Jasani MK, McCrae F, Watt I. A two-year placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee. Br J Rheumatol 1993; 32: 595600.
  • 37
    Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J, LINK Study Group. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee: Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis Study Group. J Rheumatol 1995; 22: 19416.